英語翻譯
Patient characteristics:Baseline patient characteris-tics were very similar among groups.Table 1 shows characteristics by drug assignment.Of the 2,431 pa-tients randomized to treatment,94% completed the 6-week trial (Figure 1).Drug compliance as assessed by tablet counts was similar among treatments,and means of tablets taken ranged from 90.5% to 95.3%.
Efficacy:According to the dose-response analyses,mean differences between the LDL cholesterol dose-response slopes of rosuvastatin 10 to 80 mg versus atorvastatin 10 to 80 mg and pravastatin 10 to 40 mg were significant (both p 0.001) (Figure 2).The log- dose slopes of rosuvastatin and simvastatin were not parallel,but equivalent doses were significantly dif- ferent (Figure 2).All differences that were 6% were considered clinically significant.
In the pairwise,dose-to-dose comparisons with atorvastatin,rosuvastatin 10 mg reduced LDL choles- terol significantly more than atorvastatin 10 mg,rosu- vastatin 20 mg reduced LDL cholesterol significantly more than atorvastatin 20 and 40 mg,and rosuvastatin
40 mg reduced LDL cholesterol significantly more than atorvastatin 40 mg (Table 2).In all but 1 of the other pairwise comparisons with atorvastatin (rosuv- astatin 10 vs atorvastatin 40 mg),rosuvastatin pro- duced numerically greater LDL cholesterol reduc- tions,but these differences were not significantly dif- ferent (Table 2).Rosuvastatin reduced LDL cholesterol significantly more than simvastatin and pravastatin in all 14 pairwise comparisons analyzed (Table 2).The best LDL cholesterol reduction (55%) was achieved in the rosuvastatin 40-mg group and was not significantly different (p 0.006) from the next highest LDL cholesterol reduction (51%) observed in the atorvastatin 80-mg group.